Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A randomised double blind placebo controlled phase II study of fulvestrant with or without
the addition of vandetanib as treatment for patients with metastatic breast cancer resistant
to aromatase inhibitor therapy.